News
Third time lucky for Replimune as FDA OKs melanoma drug
At its third attempt, Replimune has finally won FDA approval for its advanced melanoma treatment RP1, now named Tudriqev and its first product.
News
LifeMine gets $263m for transplant drug, and other financing...
Recent biotech financings are headed by LifeMine's $263m for a transplant drug, with Expedition, Ratio, Vedanta, and Mironid also in on the action.
News
NICE breast cancer criteria missing patients, claims study
NICE's criteria to decide who is referred for further breast cancer risk assessment miss up to 95% of younger women who go on to develop the disease.
News
Pathos AI signs two cancer deals with Alphamab and AZ
Pathos AI has grown its oncology pipeline by licensing a bispecific ADC from Alphamab for $125m and partnering a breast cancer drug from AstraZeneca.
News
Curium strikes $8bn deal to buy radiopharma rival Lantheus
Two players in the radiopharma sector, Curium and Lantheus, have agreed to merge and create an end-to-end player in diagnostics and therapeutics.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
